GO:0042568 insulin-like growth factor binary complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042568 describes a two-protein complex of approximately 50 kDa consisting of an insulin-like growth factor (IGF) and one of IGFBP-1, -2, -4, or -6.
• Binary IGF/IGFBP complexes regulate the availability of IGFs for receptor binding and thus influence growth, development, and metabolism.
• The binary complex is distinct from the ternary 150-kDa complex formed by IGFBP-3 or IGFBP-5 with IGF and the acid-labile subunit (ALS).
• Formation of the binary complex can be modulated by glycosaminoglycans and structural determinants in the IGFBP carboxyl-terminal domain.
• Serum IGF/IGFBP complexes modulate skeletal integrity and carbohydrate metabolism, linking the complex to bone and metabolic physiology.
• Studying GO:0042568 requires methods that resolve protein-protein interactions and IGF bioavailability, such as co-immunoprecipitation, size-exclusion chromatography, and CRISPR-based gene editing.
Description
The insulin-like growth factor binary complex (GO:0042568) is a cellular component defined as a two-protein assembly of approximately 50 kDa that consists of an insulin-like growth factor (IGF) and one of the insulin-like growth factor binding proteins IGFBP-1, IGFBP-2, IGFBP-4, or IGFBP-6. This complex is a fundamental unit in the IGF system, where binding proteins sequester IGFs and modulate their interaction with IGF receptors, thereby influencing growth and development. Unlike the ternary 150-kDa complex that includes IGFBP-3 or IGFBP-5 and the acid-labile subunit (ALS), the binary complex lacks ALS and represents a simpler, more dynamic carrier form. Researchers study GO:0042568 because it sits at the interface of endocrine and autocrine/paracrine IGF action. The binary complex determines how much free IGF is available to tissues, and its composition can shift in physiological states such as hibernation, where circulating IGF system adaptations indicate increased tissue IGF availability. In pathological contexts, altered binary complex formation has been linked to tumor hypoglycemia and metabolic disturbances. Understanding the assembly, regulation, and functional consequences of the IGF binary complex is therefore essential for endocrinology, metabolism, and cancer biology. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0042568, covering its structure, molecular mechanism, key genes, disease relevance, and experimental approaches including CRISPR-based models.
insulin-like growth factor binary complex At A Glance
| GO ID | GO:0042568 |
|---|---|
| GO term | insulin-like growth factor binary complex |
| Ontology | cellular_component |
| Synonym | IGF binary complex |
| Definition | A complex of two proteins, which in animals is 50kDa and consists of the insulin-like growth factor (IGF) and one of the insulin-like growth factor binding protein-1 (IGFBP-1), -2 (IGFBP-2), -4 (IGFBP-4) and -6 (IGFBP-6). The complex plays a role in growth and development. |
| Major function | Modulates IGF bioavailability and signaling in growth and development |
| Complex size | Approximately 50 kDa |
| Binding partners | IGFBP-1, IGFBP-2, IGFBP-4, IGFBP-6 |
| Related complexes | Ternary 150-kDa complex with IGFBP-3/IGFBP-5 and ALS |
What Is GO:0042568?
GO:0042568 (insulin-like growth factor binary complex) is a cellular component ontology term describing a protein complex of approximately 50 kDa composed of two proteins: an insulin-like growth factor (IGF) and one insulin-like growth factor binding protein from the subset IGFBP-1, IGFBP-2, IGFBP-4, or IGFBP-6. The complex plays a role in growth and development by modulating IGF bioavailability. It is synonymous with the IGF binary complex and is distinct from ternary complexes that include ALS.
Why Is insulin-like growth factor binary complex Important in Cell Biology?
The insulin-like growth factor binary complex is important because it controls the amount of free IGF available to activate IGF receptors, thereby influencing cell growth, survival, and metabolism. Dysregulation of this complex has been implicated in tumor hypoglycemia and metabolic disorders, and its modulation is relevant to skeletal integrity and carbohydrate metabolism. Understanding GO:0042568 helps researchers interpret how IGFBPs act as gatekeepers of IGF action in both health and disease.
• Regulates IGF bioavailability and receptor activation in growth and development.
• Distinct from ternary complexes involving ALS, allowing differential regulation of IGF transport.
• Modulated by glycosaminoglycans, linking extracellular matrix to IGF signaling.
• Involved in tumor hypoglycemia through IGF-II/IGFBP interactions.
• Serum IGF/IGFBP complexes influence skeletal integrity and carbohydrate metabolism.
• Adaptations in circulating IGF system during hibernation indicate physiological regulation of binary complexes.
• IGFBP-4 and IGFBP-6 have unique structural features affecting binary complex formation.
• IGFBP-5 can form complexes with ALS, highlighting specificity among IGFBPs.
• Provides a target for therapeutic modulation of IGF activity in cancer and metabolic disease.
• Essential for interpreting endocrine and paracrine IGF actions in vivo.
What Happens During insulin-like growth factor binary complex?
Formation of the binary complex
In simple terms: An IGF molecule binds to a specific IGFBP to form a two-protein carrier.
The binary complex forms when an IGF (IGF-I or IGF-II) binds non-covalently to one of the IGFBPs -1, -2, -4, or -6. This interaction is driven by structural determinants in both the IGF and the IGFBP, and results in a complex of approximately 50 kDa. The binary complex can exist in circulation and in extracellular fluids, where it modulates IGF availability.
Structural determinants of binding
In simple terms: Specific parts of the IGFBP protein determine whether it can bind IGF and form a binary complex.
Studies on IGFBP-3 have identified structural determinants for binary and ternary complex formation, including regions in the carboxyl-terminal domain. For IGFBP-5, the carboxyl-terminal domain is also critical for complex formation with ALS. These structural features are likely shared among IGFBPs that form binary complexes, although the exact determinants for IGFBP-1, -2, -4, and -6 may differ.
Modulation by glycosaminoglycans
In simple terms: Certain sugar chains in the extracellular matrix can inhibit the formation of IGFBP complexes.
Glycosaminoglycans have been shown to inhibit the formation of the 140 kDa IGF-binding protein complex, indicating that extracellular matrix components can regulate binary complex assembly. This suggests that the tissue microenvironment can influence IGF bioavailability by affecting binary complex formation.
Distinction from ternary complexes
In simple terms: Some IGFBPs can form larger complexes with an additional protein called ALS, but the binary complex does not include ALS.
The binary complex is distinct from the ternary 150-kDa complex that includes IGFBP-3 or IGFBP-5, IGF, and the acid-labile subunit (ALS). Formation of the 150-kDa binary complexes of IGFBP-3 and ALS has been studied in vitro and in vivo, highlighting that ALS is not part of the GO:0042568 binary complex. This distinction is important for understanding IGF transport and regulation.
Physiological roles and regulation
In simple terms: The binary complex helps control how much IGF is free to act on tissues, and its levels can change with physiological state.
Serum complexes of IGF-1 modulate skeletal integrity and carbohydrate metabolism, demonstrating that binary complexes have systemic effects. In hibernating brown bears, circulating IGF system adaptations indicate increased tissue IGF availability, suggesting dynamic regulation of binary complexes. In pathological states such as tumor hypoglycemia, IGF-II and IGFBPs form binary complexes that can contribute to hypoglycemia.
Key Genes Involved in GO:0042568 insulin-like growth factor binary complex
The key genes and proteins involved in the insulin-like growth factor binary complex include the IGF ligands and the IGFBPs that form the complex, as well as associated factors that regulate their availability.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IGF1 | Ligand that binds IGFBPs to form binary complex | Studied for growth, metabolism, and skeletal integrity |
| IGF2 | Ligand that binds IGFBPs; involved in tumor hypoglycemia | Implicated in hypoglycemia and cancer |
| IGFBP1 | Forms binary complex with IGF; regulates IGF bioavailability | Marker of metabolic status and IGF action |
| IGFBP2 | Forms binary complex with IGF; modulates IGF signaling | Linked to growth and cancer |
| IGFBP3 | Forms ternary complex with ALS; also binary complex | Key carrier in serum; structural studies |
| IGFBP4 | Forms binary complex with IGF; inhibits IGF action | Role in growth and development |
| IGFBP5 | Forms complexes with ALS; binary complex with IGF | Structural determinants for complex formation |
| IGFBP6 | Forms binary complex with IGF; inhibits IGF-II | Unique binding specificity |
| ALS | Acid-labile subunit; forms ternary complex with IGFBP-3/5 | Distinguishes ternary from binary complexes |
| IGF1R | Receptor for IGFs; activated by free IGF | Downstream signaling of IGF action |
| INS | Insulin; related to IGF system in metabolism | Metabolic context of IGF complexes |
| GH | Growth hormone; regulates IGF and IGFBP production | Endocrine regulation of IGF system |
| PAPPA | Protease that cleaves IGFBP-4 | Regulates IGF bioavailability |
| PAPP-A2 | Protease that cleaves IGFBP-5 | Regulates IGF bioavailability |
| STC1 | Stanniocalcin-1; modulates IGFBP complexes | Potential regulator of binary complex |
| STC2 | Stanniocalcin-2; modulates IGFBP complexes | Potential regulator of binary complex |
| TGFB1 | Regulates IGFBP expression | Crosstalk with IGF system |
How Is insulin-like growth factor binary complex Regulated?
The formation and stability of the insulin-like growth factor binary complex are regulated at multiple levels. Structural determinants in IGFBPs, particularly the carboxyl-terminal domain, influence binding to IGF and ALS. Glycosaminoglycans can inhibit the formation of IGFBP complexes, providing extracellular matrix control. Proteases such as PAPP-A and PAPP-A2 cleave specific IGFBPs, releasing IGF and reducing binary complex levels. Hormonal factors including growth hormone and insulin regulate the expression of IGFs and IGFBPs, thereby affecting binary complex abundance. Physiological states such as hibernation can alter circulating IGF system components, indicating dynamic regulation of binary complexes.
insulin-like growth factor binary complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IGF2 | Tumor hypoglycemia | Knockout of IGF2 in cancer cell lines to assess binary complex formation |
| IGFBP1 | Metabolic syndrome | Overexpression of IGFBP1 in hepatocytes to study binary complex effects |
| IGFBP2 | Cancer progression | CRISPR knockout of IGFBP2 in tumor cells to evaluate IGF bioavailability |
| IGFBP4 | Growth retardation | Point mutation in IGFBP4 to disrupt IGF binding |
| IGFBP6 | Cancer and growth | Knock-in of tagged IGFBP6 to track binary complex localization |
Tumor hypoglycemia
Tumor hypoglycemia is a paraneoplastic syndrome often caused by excessive production of IGF-II, which forms binary complexes with IGFBPs and can lead to increased free IGF-II or insulin-like activity. The binary complex plays a role in the pathogenesis by modulating IGF-II bioavailability and receptor activation.
Metabolic and skeletal disorders
Serum complexes of IGF-1 modulate skeletal integrity and carbohydrate metabolism, and alterations in binary complex formation may contribute to bone and metabolic diseases. Understanding how IGFBPs and IGFs assemble into binary complexes is relevant to conditions such as osteoporosis and insulin resistance.
Cancer
IGFBPs that form binary complexes can either inhibit or promote cancer progression depending on context. For example, IGFBP-4 and IGFBP-6 generally inhibit IGF action, while IGFBP-2 may promote tumor growth. The binary complex thus represents a node for therapeutic intervention in IGF-driven cancers.
From insulin-like growth factor binary complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IGFBP-1 form binary complexes with IGF-I in vivo? | IGFBP1 knockout mouse |
| What is the role of IGFBP-2 in cancer cell proliferation? | IGFBP2 knockout cancer cell line |
| How does a point mutation in IGFBP-4 affect IGF binding? | Point mutation knock-in in cell lines |
| Can we track binary complex localization in real time? | Tagged knock-in of IGFBP-6 with fluorescent protein |
| Does overexpression of IGFBP-6 inhibit IGF-II signaling? | IGFBP6 overexpression cell model |
| What is the effect of ALS on binary vs ternary complex formation? | ALS knockout mouse |
How to Study the insulin-like growth factor binary complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Protein-protein interactions | Detecting binary complexes in cell lysates |
| Size-exclusion chromatography | Molecular size and complex formation | Separating binary from ternary complexes |
| Surface plasmon resonance | Binding affinity and kinetics | Studying IGF-IGFBP interactions |
| Western blotting | Protein abundance and complex components | Validating binary complex partners |
| ELISA | Quantification of IGF/IGFBP levels | Measuring serum binary complex components |
| CRISPR knockout | Gene function loss | Assessing IGFBP role in binary complex |
| CRISPR knock-in | Tagged protein expression | Tracking binary complex localization |
| Overexpression | Gain of function | Testing IGFBP effects on IGF signaling |
Co-immunoprecipitation and Western blotting
Co-immunoprecipitation followed by Western blotting can detect binary complexes of IGF and IGFBPs in cell lysates or serum. This method uses antibodies against IGF or specific IGFBPs to pull down the complex and identify partners.
Size-exclusion chromatography
Size-exclusion chromatography separates proteins by size and can resolve the approximately 50 kDa binary complex from free IGF, free IGFBP, and larger ternary complexes. This technique is useful for quantifying binary complex formation in vitro.
Surface plasmon resonance (SPR)
SPR measures real-time binding kinetics between IGFs and IGFBPs, providing affinity constants and structural insights into binary complex formation. It is used to study the effects of mutations in IGFBPs on binding.
CRISPR-based gene editing
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of genes encoding IGFs and IGFBPs in the context of binary complex biology. These models can be used to test how specific domains contribute to complex formation and downstream signaling.
How CRISPR Can Be Used to Study GO:0042568 insulin-like growth factor binary complex
Knockout
CRISPR knockout of IGFBP genes (e.g., IGFBP1, IGFBP2, IGFBP4, IGFBP6) can eliminate binary complex formation and reveal their roles in IGF bioavailability and downstream signaling. Knockout models are useful for studying loss-of-function phenotypes in growth and metabolism.
Point Mutation
Point mutations can be introduced into IGFBP genes to disrupt specific residues involved in IGF binding, allowing precise mapping of structural determinants for binary complex formation. Such models help distinguish binary from ternary complex formation.
Knock-in
Knock-in of tagged IGFBP or IGF alleles (e.g., fluorescent or epitope tags) enables visualization and purification of binary complexes from cells or tissues. This approach facilitates tracking of complex assembly and localization.
Overexpression
Overexpression of IGFBPs or IGFs can drive increased binary complex formation and modulate IGF signaling in vitro and in vivo. Overexpression models are valuable for testing therapeutic hypotheses in cancer and metabolic disease.
How EDITGENE Supports insulin-like growth factor binary complex Research
Researchers studying insulin-like growth factor binary complex-related genes often need to determine whether a candidate gene is causally involved in complex formation, IGF bioavailability, or downstream phenotypes. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for insulin-like growth factor binary complex research.
Frequently Asked Questions About insulin-like growth factor binary complex
What is GO:0042568?
GO:0042568 is the Gene Ontology term for insulin-like growth factor binary complex, a two-protein complex of about 50 kDa consisting of an IGF and one of IGFBP-1, -2, -4, or -6.
What genes are involved in insulin-like growth factor binary complex?
The main genes are IGF1, IGF2, IGFBP1, IGFBP2, IGFBP4, and IGFBP6, which encode the ligands and binding proteins that form the binary complex.
How is the insulin-like growth factor binary complex different from the ternary complex?
The binary complex contains only IGF and an IGFBP, whereas the ternary complex includes IGF, IGFBP-3 or -5, and the acid-labile subunit (ALS).
What is the function of the IGF binary complex?
It modulates IGF bioavailability and signaling, playing roles in growth, development, and metabolism.
Which diseases are associated with the IGF binary complex?
It has been linked to tumor hypoglycemia, metabolic disorders, and cancer.
How can I study the IGF binary complex in the lab?
Common methods include co-immunoprecipitation, size-exclusion chromatography, surface plasmon resonance, and CRISPR-based gene editing.
What is the molecular weight of the IGF binary complex?
The binary complex is approximately 50 kDa.
Does IGFBP-3 form a binary complex?
Yes, IGFBP-3 can form binary complexes with IGF, but it also forms ternary complexes with ALS.
Can glycosaminoglycans affect the IGF binary complex?
Yes, glycosaminoglycans have been shown to inhibit the formation of IGFBP complexes.
What CRISPR models are available for IGF binary complex research?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening services for genes involved in the IGF binary complex.
Conclusion
The insulin-like growth factor binary complex (GO:0042568) is a key regulatory unit in the IGF system, controlling IGF bioavailability and influencing growth, metabolism, and disease. Its assembly is governed by structural determinants in IGFBPs and can be modulated by extracellular factors such as glycosaminoglycans. Dysregulation of binary complexes is implicated in tumor hypoglycemia, metabolic disorders, and cancer, making it a relevant target for research. CRISPR-based models provide powerful tools to dissect the function of IGFs and IGFBPs in binary complex formation and downstream signaling. EDITGENE offers a comprehensive suite of CRISPR services, including knockout, point mutation, knock-in, overexpression, and library screening, to support mechanistic and translational studies on the IGF binary complex. By combining precise gene editing with bioinformatics, researchers can accelerate discoveries in this important area of endocrinology and oncology.
References
- 1. Bach LA. 2015. Insulin-like growth factor binding proteins 4-6.. Best Pract Res Clin Endocrinol Metab 29(5):713-22 PMID: 26522456
- 2. Frøbert AM et al.. 2022. Circulating insulin-like growth factor system adaptations in hibernating brown bears indicate increased tissue IGF availability.. Am J Physiol Endocrinol Metab 323(3):E307-E318 PMID: 35830688
- 3. Baxter RC et al.. 1992. Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3.. J Biol Chem 267(1):60-5 PMID: 1370451
- 4. Baxter RC. 1996. The role of insulin-like growth factors and their binding proteins in tumor hypoglycemia.. Horm Res 46(4-5):195-201 PMID: 8950621
- 5. Lee CY et al.. 1995. Formation of 150-kDa binary complexes of insulin-like growth factor binding protein-3 and the acid-labile subunit in vitro and in vivo.. Prog Growth Factor Res 6(2-4):241-51 PMID: 8817667
- 6. Yakar S et al.. 2009. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.. FASEB J 23(3):709-19 PMID: 18952711
- 7. Baxter RC. 1990. Glycosaminoglycans inhibit formation of the 140 kDa insulin-like growth factor-binding protein complex.. Biochem J 271(3):773-7 PMID: 1700901
- 8. Twigg SM et al.. 1998. Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain.. J Biol Chem 273(44):28791-8 PMID: 9786878
